PT  - JOURNAL ARTICLE
AU  - Ciulei, Mihaela A.
AU  - Zhou, Shouhao
AU  - Gallagher, Kelly
AU  - Taneja, Sunita
AU  - Bhandari, Nita
AU  - Kolsteren, Patrick
AU  - Muhammad, Ameer
AU  - Tielsch, James M
AU  - Argaw, Alemayehu
AU  - Chowdhury, Ranadip
AU  - Christian, Parul
AU  - Dailey-Chwalibóg, Trenton
AU  - de Kok, Brenda
AU  - Erchick, Daniel J.
AU  - Jehan, Fyezah
AU  - Katz, Joanne
AU  - Khatry, Subarna
AU  - Lachat, Carl
AU  - Lama, Tsering P
AU  - Nisar, Muhammad Imran
AU  - Shafiq, Yasir
AU  - Upadhyay, Ravi
AU  - Gernand, Alison D
AU  - ,
TI  - The effect of balanced energy-protein supplementation provided to lactating women on maternal and infant outcomes: study protocol for a prospectively planned individual patient data (IPD) meta-analysis
AID  - 10.1101/2023.11.06.23298006
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.06.23298006
4099  - http://medrxiv.org/content/early/2023/11/06/2023.11.06.23298006.short
4100  - http://medrxiv.org/content/early/2023/11/06/2023.11.06.23298006.full
AB  - Background The high prevalence of infant stunting and maternal undernutrition in low- and middle-income countries poses a significant public health threat. The World Health Organization recommends balanced energy-protein (BEP) supplementation to pregnant women from populations with a high prevalence of underweight (prepregnancy BMI <18.5 kg/m2), leaving a notable gap in guidance for lactating women. To address this problem, we established the Maternal BEP Studies Harmonization Initiative (BEP Initiative) to investigate the impact of BEP supplementation given to pregnant and/or lactating women on maternal and infant outcomes by synthesizing data from multiple clinical trials. This is a study protocol for our prospective individual participant data (IPD) meta-analysis on BEP lactation trials.Methods Data from four randomized controlled trials that include mother-infant dyads in India (n=816), Pakistan (n=957), Burkina Faso (n=800), and Nepal (n=726) will be pooled and analyzed. Women were randomized to BEP (one trial had a third arm with maternal BEP plus infants receiving azithromycin) or control groups at baseline (during the first week) and received the intervention through six months postpartum. A one-stage IPD meta-analysis will be done using mixed-effects linear and log-binomial regression models to account for between-trial heterogeneity. The primary outcome of infant length-for-age z scores (LAZ) at six months of age and secondary outcomes of maternal and infant indicators of nutritional status at six months of age will be examined. Also, we will examine baseline characteristics as covariates and effect modifiers for the BEP to outcome relationship. Risk of bias assessments will be carried out for each of the individual trials using the Cochrane risk of bias tool.Discussion This prospective IPD meta-analysis uses a one-stage IPD meta-analysis, which allows for higher statistical power to examine outcomes, more flexibility in defining variables, and has the ability to examine many individual- and study-level variables as effect modifiers, allowing conclusions on which individuals or populations may benefit more from BEP given during lactation.Trial registration This protocol was pre-registered in Open Science Framework (https://osf.io/9nq7z)Competing Interest StatementAll authors have been funded by the Bill & Melinda Gates Foundation. Parul Christian worked at the BMGF from 2015-2019 during which the BEP trials were funded. All other authors, co-authors, and collaborators have nothing to declare. JT participated on a Data Safety Monitoring Board or Advisory Board at University of North Carolina and University of California San Francisco on studies unrelated to this manuscript. JT was a non-profit board member, unpaid, for the Helen Keller International, which may use the results of these trials, depending on the results, in their programming. JT was a non-profit board member, unpaid, for the Health Volunteers Overseas that conducts work unrelated to the topic of this manuscript.Clinical Protocols https://osf.io/9nq7z Funding StatementThis work was funded by the Bill & Melinda Gates Foundation, investment grant number INV-022373. The funder had no role in the study design, collection, analysis, and interpretation of data and in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For each individual trial, local ethical approval was obtained. This IPD meta-analysis will use de-identified data (deemed exempt from ethical approval by the Institutional Review Board at Penn State). The de-identified and harmonized IPD meta-analysis dataset will be stored in a data repository. The research findings will be disseminated in peer-reviewed, open-access journals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo data available at this stageAGPalpha-1-acid glycoproteinBEPbalanced energy-proteinBMGFBill & Melinda Gates FoundationBMIBody Mass IndexCRPC-reactive proteinIFAiron and folic acidIPDindividual participant dataLAZlength-for-age z-scoreLMIClow and middle-income countriesMUACmid-upper arm circumferenceRCTrandomized controlled trialWAZweight-for-age z-scoreWHOWorld Health OrganizationWLZweight-for-length z-score